Heng et al evaluated patients with metastatic renal cell carcinoma who were treated with vascular endothelial growth factors (VEGF) targeted therapy. The authors are from multiple institutions in the United States and Canada.
Patient selection: metastatic renal cell carcinoma treated with VEGF targeted therapy
Parameters:
(1) Karnofsky Performance Scale (KPS)
(2) time from diagnosis to treatment
(3) hemoglobin in g/dL
(4) serum calcium in mg/dL
(5) absolute neutrophil count per µL
(6) platelet count per µL
Parameter
Finding
Points
Karnofsky Performance Scale
>= 80%
0
< 80%
1
time from diagnosis
< 1 year
>= 1 year
hemoglobin
< LLN
>= LLN
serum calcium
<= ULN
> ULN
neutrophil count
platelet count
total score =
= SUM(points for all 6 parameters)
Interpretation:
• minimum score: 0
• maximum score: 6
• The higher the score the worse the prognosis.
Score
Risk Group
2-Year Overall Survival
favorable
75%
1 or 2
intermediate
53%
3 to 6
poor
7%
Performance:
• The area under the ROC curve is 0.73.
To read more or access our algorithms and calculators, please log in or register.
Purpose: To evaluate a patient for a hepatocellular carcinoma using the up-to-seven criteria of Mazzaferro et al.
Specialty: Hematology Oncology
Objective: severity, prognosis, stage
ICD-10: C64,
